Zhang J, Li S, Cheng X, Tan X, Shi Y, Su G
Int J Mol Sci. 2025; 26(5).
PMID: 40076847
PMC: 11900916.
DOI: 10.3390/ijms26052225.
Xiang J, An Y, Sun J, Xu J, Xiong Y, Wang S
Discov Oncol. 2025; 16(1):279.
PMID: 40055297
PMC: 11889302.
DOI: 10.1007/s12672-025-02021-4.
Xu Y, Ning L, Si Y, Li X, Wang R, Ren Q
Front Endocrinol (Lausanne). 2025; 16:1526109.
PMID: 40041289
PMC: 11876036.
DOI: 10.3389/fendo.2025.1526109.
Feng J, Shao W, Yang L, Pang J, Ling W, Liu D
Nutr Diabetes. 2025; 15(1):4.
PMID: 39929809
PMC: 11811165.
DOI: 10.1038/s41387-025-00363-0.
Guerbette T, Ciesielski V, Brien M, Catheline D, Viel R, Bostoen M
Mol Metab. 2025; 92:102098.
PMID: 39814101
PMC: 11795564.
DOI: 10.1016/j.molmet.2025.102098.
Meeting metformin again for the first time.
Green D
Sci Adv. 2024; 10(51):eadu7436.
PMID: 39693446
PMC: 11654691.
DOI: 10.1126/sciadv.adu7436.
Growth hormone attenuates obesity and reshapes gut microbiota in high-fat diet-fed mice.
Wang Y, Ran L, Zhang F, Li H, Cha Q, Yang K
Metabol Open. 2024; 24:100326.
PMID: 39513179
PMC: 11541824.
DOI: 10.1016/j.metop.2024.100326.
Metformin: Diverse molecular mechanisms, gastrointestinal effects and overcoming intolerance in type 2 Diabetes Mellitus: A review.
Mohamed S
Medicine (Baltimore). 2024; 103(43):e40221.
PMID: 39470509
PMC: 11521032.
DOI: 10.1097/MD.0000000000040221.
Hormone based therapy and crosstalk beyond hormones.
Jin T
Med Rev (2021). 2024; 4(4):257-261.
PMID: 39135606
PMC: 11317080.
DOI: 10.1515/mr-2024-0052.
Cryptotanshinone promotes brown fat activity by AMPK activation to inhibit obesity.
Ni J, Ye A, Gong L, Zhao X, Fu S, Guo J
Nutr Res Pract. 2024; 18(4):479-497.
PMID: 39109201
PMC: 11300114.
DOI: 10.4162/nrp.2024.18.4.479.
Data-dependent and -independent acquisition lipidomics analysis reveals the tissue-dependent effect of metformin on lipid metabolism.
Scheidemantle G, Duan L, Lodge M, Cummings M, Hilovsky D, Pham E
Metabolomics. 2024; 20(3):53.
PMID: 38722395
PMC: 11145978.
DOI: 10.1007/s11306-024-02113-2.
Lipotoxicity as a therapeutic target in obesity and diabetic cardiomyopathy.
Nakamura M
J Pharm Pharm Sci. 2024; 27:12568.
PMID: 38706718
PMC: 11066298.
DOI: 10.3389/jpps.2024.12568.
Gut microbiota and therapy for obesity and type 2 diabetes.
Zhang L, Wang P, Huang J, Xing Y, Wong F, Suo J
Front Endocrinol (Lausanne). 2024; 15:1333778.
PMID: 38596222
PMC: 11002083.
DOI: 10.3389/fendo.2024.1333778.
Metformin plus L-carnitine enhances brown/beige adipose tissue activity via Nrf2/HO-1 signaling to reduce lipid accumulation and inflammation in murine obesity.
Liang G, Fang J, Zhang P, Ding S, Zhao Y, Feng Y
Open Med (Wars). 2024; 19(1):20240900.
PMID: 38463531
PMC: 10921440.
DOI: 10.1515/med-2024-0900.
AMPK, a key molecule regulating aging-related myocardial ischemia-reperfusion injury.
Yin X, Guo Z, Song C
Mol Biol Rep. 2024; 51(1):257.
PMID: 38302614
DOI: 10.1007/s11033-023-09050-8.
Metformin: The Winding Path from Understanding Its Molecular Mechanisms to Proving Therapeutic Benefits in Neurodegenerative Disorders.
Isop L, Neculau A, Necula R, Kakucs C, Moga M, Dima L
Pharmaceuticals (Basel). 2023; 16(12).
PMID: 38139841
PMC: 10748332.
DOI: 10.3390/ph16121714.
Gut microbiota intervention attenuates thermogenesis in broilers exposed to high temperature through modulation of the hypothalamic 5-HT pathway.
Li S, Li X, Wang K, Li Y, Nagaoka K, Li C
J Anim Sci Biotechnol. 2023; 14(1):159.
PMID: 38129919
PMC: 10734199.
DOI: 10.1186/s40104-023-00950-0.
Brown Fat and Nutrition: Implications for Nutritional Interventions.
Noriega L, Yang C, Wang C
Nutrients. 2023; 15(18).
PMID: 37764855
PMC: 10536824.
DOI: 10.3390/nu15184072.
Reg3γ: current understanding and future therapeutic opportunities in metabolic disease.
Shin J, Bozadjieva-Kramer N, Seeley R
Exp Mol Med. 2023; 55(8):1672-1677.
PMID: 37524871
PMC: 10474034.
DOI: 10.1038/s12276-023-01054-5.
A gut feeling for drugs that have metabolic benefits.
Zhang E, Agua A, Huang W
Nat Commun. 2023; 14(1):4464.
PMID: 37491425
PMC: 10368690.
DOI: 10.1038/s41467-023-40167-3.